About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Arizona | 16,770 Studies Near You | Clareo Health

Clinical Trials LocationsArizona

Clinical Trials in Arizona

Discover 16,770 clinical trials near Arizona. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 5421-5440 of 16,770 trials

COMPLETEDPhase 231 miles

ET-01 in Subjects With Lateral Canthal Lines, LCL-210

NCT04985916

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

Lateral Canthal Lines, LCLCrow's Feet

Eirion Therapeutics Inc.280 participantsStarted Jul 2021

Scottsdale, Arizona, United States • San Diego, California, United States • Aventura, Florida, United States +16 more locations

COMPLETEDPhase 331 miles

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

NCT03440385

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.

Celgene606 participantsStarted Mar 2018

Scottsdale, Arizona, United States • La Jolla, California, United States • Lancaster, California, United States +365 more locations

Find Trials by Condition in Arizona

Breast Cancerin Arizona Lung Cancerin Arizona Prostate Cancerin Arizona Colorectal Cancerin Arizona Melanomain Arizona Leukemiain Arizona Lymphomain Arizona Pancreatic Cancerin Arizona Ovarian Cancerin Arizona Brain Cancerin Arizona Diabetes

Data from ClinicalTrials.govTerms

COMPLETEDPhase 335 miles

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

NCT02839330

This Phase 3 study evaluates the safety, immunogenicity and lot-to lot consistency of 3 lots of aH5N1c vaccine for pandemic avian influenza, in approximately 2394 healthy adults ≥18 years of age receiving the vaccine and 797 healthy adults receiving placebo. Subjects were randomized in a 3:1 ratio to receive either aH5N1c vaccine or saline placebo. Enrollment was stratified by age: 18 to \<65 years of age and ≥65 years of age, to allow adequate safety assessment of the entire age spectrum.

Avian Influenza

Seqirus3,196 participantsStarted Jul 2016

Huntsville, Alabama, United States • Chandler, Arizona, United States • Tempe, Arizona, United States +23 more locations

TERMINATEDPhase 242 miles

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)

NCT05602727

The main purpose of this study was to assess the safety and efficacy of MK-1942 as adjunctive therapy in participants with mild to moderate Alzheimer's Disease (AD) dementia.

Alzheimer's Disease

Merck Sharp & Dohme LLC99 participantsStarted Dec 2022

Phoenix, Arizona, United States • Fullerton, California, United States • Sherman Oaks, California, United States +71 more locations

Enrolling By InvitationNA42 miles

Electrophysiological Recordings from Deep Brain Stimulation Electrodes for Pain

NCT06019793

Over the last 30 years, deep brain stimulation (DBS) has allowed tens of thousands of patients to receive relief of neurological symptoms that were refractory to standard medical treatment. Furthermore, by providing a rare window into the electrophysiological activity of the awake, human brain, DBS has facilitated invaluable advances in scientific understanding. These advances have then, in turn, allowed for further therapies to be developed for an ever growing population of patients that benefit from DBS therapy. This study hopes to add to this growing body of knowledge by implanting leads within, and recording from, the sensory thalamus and periaqueductal gray (PAG) in patients with chronic pain. Specifically, we hope to establish the long-term safety of DBS leads within the periaqueductal gray and sensory thalamus for the treatment of chronic pain. Furthermore, by recording from the electrodes of DBS patients implanted for treatment of their chronic pain, we hope to understand how the pain network responds to sensory stimuli and how DBS changes this response.

St. Joseph's Hospital and Medical Center, Phoenix50 participantsStarted Jun 2024

Phoenix, Arizona, United States

TERMINATEDPhase 342 miles

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT04944784

The purpose of this study is to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS.

Amyotrophic Lateral Sclerosis

Cytokinetics489 participantsStarted Aug 2021

Phoenix, Arizona, United States • Los Angeles, California, United States • Orange, California, United States +81 more locations

COMPLETEDPhase 242 miles

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02312245

This phase II trial studies how well Avatar-directed chemotherapy works in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that does not respond to platinum anti-cancer drugs. Drugs used in chemotherapy, such as paclitaxel, gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride, topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Using an Avatar, a living tumor sample with similar genetic characteristics to the original tumor, may help determine which chemotherapy is most effective.

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma

Mayo Clinic13 participantsStarted Jul 2015

Phoenix, Arizona, United States • Jacksonville, Florida, United States • Rochester, Minnesota, United States

COMPLETEDPhase 2108 miles

A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance

NCT02799745

The primary purpose of this study was to compare the time to prostate cancer progression (pathological or therapeutic progression) between patients treated with enzalutamide versus patients undergoing active surveillance.

Prostate Cancer

Astellas Pharma Global Development, Inc.227 participantsStarted Jun 2016

Birmingham, Alabama, United States • Homewood, Alabama, United States • Tucson, Arizona, United States +51 more locations

TERMINATEDPhase 3288 miles

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

NCT02588261

The purpose of the study was to evaluate the progression free survival (PFS), based on independent radiologic review (IRR), of ASP8273 compared to erlotinib or gefitinib in patients with locally advanced, metastatic or unresectable stage IIIB/IV adenocarcinoma non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations. This study also assessed Overall survival (OS); Overall response rate (ORR) as assessed by IRR; PFS as assessed by the investigator; Disease control rate (DCR) as assessed by IRR; Duration of Response (DOR) by IRR; Safety of ASP8273; and Quality of Life (QOL) and patient-reported outcome (PRO) parameters.

Non-small Cell Lung Cancer (NSCLC)

Astellas Pharma Global Development, Inc.530 participantsStarted Feb 2016

Beverly Hills, California, United States • Fountain Valley, California, United States • La Jolla, California, United States +164 more locations

TERMINATEDPhase 2339 miles

A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease

NCT05476783

This is an open-label long term extension study for participants with Alzheimer's disease (AD) who have completed Protocol TB006AD2102 (lead-in study) or participants who would have been eligible for the lead-in study but were not enrolled (de novo). The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TB006. The total study duration for each participant will be up to 113 weeks.

Alzheimer's Disease

TrueBinding, Inc.180 participantsStarted Sep 2022

San Diego, California, United States • Delray Beach, Florida, United States • Lady Lake, Florida, United States +10 more locations

COMPLETEDPhase 3339 miles

A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

NCT06039449

A study to investigate the prevention of COVID-19 with VYD222 in adults with immune compromise and in participants aged 12 years or older who are at risk of exposure to SARS-CoV-2

COVID-19SARS-CoV-2

Invivyd, Inc.790 participantsStarted Sep 2023

Fullerton, California, United States • Long Beach, California, United States • Rolling Hills Estates, California, United States +15 more locations

WITHDRAWNPhase 2339 miles

An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)

NCT05879614

A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Prader-Willi Syndrome.

Prader-Willi Syndrome

Neuren Pharmaceuticals LimitedStarted Sep 2023

San Diego, California, United States • Atlanta, Georgia, United States • Chevy Chase, Maryland, United States +1 more locations

COMPLETED341 miles

SpineJack System Postmarket Registry

NCT04795765

This postmarket registry is intended to prospectively collect real world data to support ongoing safety and performance of the SpineJack system.

Osteoporotic Vertebral Compression Fractures

Stryker Instruments261 participantsStarted Aug 2019

Encinitas, California, United States • Larkspur, California, United States • Stuart, Florida, United States +9 more locations

COMPLETEDPhase 1341 miles

Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment

NCT05751759

This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of mitiperstat.

Hepatic Impairment

AstraZeneca31 participantsStarted Mar 2023

Rialto, California, United States • Hialeah, Florida, United States • Orlando, Florida, United States +2 more locations

TERMINATEDPhase 2367 miles

Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies

NCT05846659

Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy (PULSAR-ICI) + IMSA101 and PULSAR-ICI alone in patients with oligoprogressive solid tumor malignancies after prior anti-cancer therapy.

Oligoprogressive

ImmuneSensor Therapeutics Inc.16 participantsStarted Jul 2023

Irvine, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +11 more locations

RECRUITING369 miles

realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

NCT04981795

The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.

Diffuse Large B-cell Lymphoma

Incyte Corporation100 participantsStarted Sep 2021

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Orange, California, United States +22 more locations

COMPLETEDPhase 4391 miles

A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma

NCT04502862

Primary Objective: To assess the effect of dupilumab on sleep Secondary Objectives: * To evaluate the effect of dupilumab on additional participant reported sleep outcomes * To evaluate the effect of dupilumab on objective sleep assessment * To evaluate the effect of dupilumab on asthma symptoms * To evaluate the effect of dupilumab on lung function * To evaluate the safety of dupilumab

Sanofi202 participantsStarted Aug 2020

Bakersfield, California, United States • Culver City, California, United States • Los Angeles, California, United States +52 more locations

COMPLETEDNA552 miles

Pragmatic Trial Examining Oxygenation Prior to Intubation

NCT05267652

Clinicians perform rapid sequence induction, laryngoscopy, and tracheal intubation for more than 5 million critically ill adults as a part of clinical care each year in the United States. One-in-ten emergency tracheal intubations is complicated by life-threatening hypoxemia. Administering supplemental oxygen prior to induction and intubation ("preoxygenation") decreases the risk of life-threatening hypoxemia. In current clinical practice, the most common methods for preoxygenation are non-invasive positive pressure ventilation and facemask oxygen. Prior trials comparing non-invasive positive pressure ventilation and facemask oxygen for preoxygenation have been small and have yielded conflicting results. A better understanding of the comparative effectiveness of these two common, standard-of-care approaches to preoxygenation could improve the care clinicians deliver and patient outcomes.

Acute Respiratory Failure

Vanderbilt University Medical Center1,301 participantsStarted Mar 2022

Birmingham, Alabama, United States • Aurora, Colorado, United States • Iowa City, Iowa, United States +13 more locations

Active Not RecruitingPhase 3552 miles

SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma

NCT04967521

This is a Phase 3 randomized double-blind study of abemaciclib versus placebo. Patients with progression of disease will cross over to open label abemaciclib.

Advanced Dedifferentiated Liposarcoma

Sarcoma Alliance for Research through Collaboration108 participantsStarted Nov 2021

Aurora, Colorado, United States • Jacksonville, Florida, United States • Chicago, Illinois, United States +6 more locations

COMPLETEDPhase 1730 miles

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

NCT06050928

This phase 1b trial will evaluate the effects of EP262 in subjects with Chronic Inducible Urticaria (CIndU), including symptomatic dermographism and cold urticaria.

Chronic Inducible Urticaria

Escient Pharmaceuticals, Inc33 participantsStarted Aug 2023

Tampa, Florida, United States • Boise, Idaho, United States • Owensboro, Kentucky, United States +12 more locations

PreviousPage 272 of 839Next

in Arizona

Heart Diseasein Arizona